Updated:
Deerland Enzymes
Deerland Enzymes is a Kennesaw-based enzyme manufacturer for agriculture and food processing, with undisclosed ownership and no fund activity.
Deerland Enzymes
Deerland Enzymes is headquartered in Kennesaw, Georgia, and describes itself as a manufacturer of enzyme-based solutions for industries including agriculture, food processing, and animal nutrition. The firm's product line includes bromelain, papain, and other protease enzymes used in grain milling, brewing, animal feed digestion, and plant-based protein extraction. Its facilities produce bulk enzyme ingredients sold to food and feed manufacturers globally, with a presence across North America and select European markets. While Deerland Enzymes operates as an industrial biotech manufacturer, its exact ownership structure and AUM remain undisclosed in public sources. The firm does not publicly report a team size or named executives beyond general leadership roles associated with its production capabilities. No recent operational events are available in public record for the past 24 months as of May 2026. Deerland Enzymes holds no disclosed fund vehicles, co-investment structures, or separately managed accounts. Its business model centers on revenue from enzyme sales rather than capital deployment, placing it outside traditional asset management or family office frameworks. The firm lacks a known philanthropic foundation, club membership, or spinout vehicles. The company's differentiator lies in its proprietary enzyme production and its positioning as a contract supplier to the alternative-protein and animal-feed industries, though its exact relationship with investment capital remains opaque. No succession or governance details are publicly available.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Kennesaw
Corporate office
Kennesaw, GA, United States
Sector focus
Frequently asked questions
What does Deerland Enzymes produce?
Deerland Enzymes manufactures enzyme blends including bromelain, papain, and proteases for use in grain milling, animal feed digestion, and plant-based protein extraction. Its products are sold as ingredients to food and feed manufacturers (per the firm's product literature).
Is Deerland Enzymes an investment firm or a manufacturer?
Deerland Enzymes operates as an industrial biotech manufacturer, not an investment manager. It generates revenue through enzyme sales rather than deploying capital, meaning it does not fit the standard family office or asset manager model (Altss estimate).
Does Deerland Enzymes participate in fund commitments or direct deals?
No public records indicate fund commitments or direct investment activity by Deerland Enzymes. Its business focuses on contract manufacturing and ingredient supply, with no disclosed involvement in private equity or venture capital (public record).
Who leads Deerland Enzymes?
Named executives for Deerland Enzymes are not publicly available in press releases or official documents as of May 2026. The firm's leadership structure remains undisclosed (public record).
What sectors does Deerland Enzymes serve?
Deerland Enzymes serves the agriculture, food processing, and animal nutrition sectors, with products used in grain milling, brewing, and feed digestion. It also supports the alternative-protein supply chain via plant-based protein extraction (per the firm's product literature).
Where is Deerland Enzymes located?
Deerland Enzymes is headquartered in Kennesaw, Georgia, United States. No additional office locations have been publicly disclosed (public record).
How does Deerland Enzymes source its raw materials?
Deerland Enzymes uses proprietary fermentation and extraction processes to produce its enzyme blends, sourcing biological raw materials from agricultural suppliers. Specific procurement details are not publicly disclosed (public record).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: